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956immortal time bias (2) and subsequently affected
the results of the study. To address this concern, as
suggested in their letter to the editor, we reanalyzed
the data after matching for propensity score and
being alive on the day of ﬁlter placement. We
identiﬁed 8 patients (8 of 344 [2.3%]; 95% conﬁdence
interval [CI]: 0.7% to 3.9%) in the control group
who died before insertion of the ﬁlter, and we
removed the matched pairs from the reanalysis. The
propensity-based matching of patients yielded 336
patients with an inferior vena cava ﬁlter and 336
patients without a ﬁlter. We did not detect a
difference in mortality between patients who
received a ﬁlter and those who did not (6.8% vs.
8.9%; risk difference: 2.1% [95% CI: 6.3% to 2.0%];
p ¼ 0.32), although the clinically relevant trend
favored treatment with a ﬁlter. Analysis of propensity
score–matched pairs showed a statistically signiﬁcant
lower risk of pulmonary embolism–related mortality
for patients with a ﬁlter compared with those
without a ﬁlter (0.9% vs. 3.3%; risk difference: 2.4%
[95% CI: 4.9% to 0.2%]; p ¼ 0.04). Thus, after
addressing the concerns outlined in the letter to the
editor, we have results and conclusions similar to
those described in the study report (1).
A randomized trial is a powerful tool because it
enables clinical researchers to evaluate the efﬁcacy of
therapies without worrying about unmeasured con-
founders and some types of bias such as immortal
time bias. Although we agree that a randomized
controlled trial would provide the strongest evidence
regarding the efﬁcacy and safety of inferior vena cava
ﬁlters in patients with an acute venous thromboem-
bolism and a contraindication to anticoagulation, the
ethical issues associated with using a no-treatment
control group would likely prevent the performance
of such a trial. If it is not feasible to conduct a well-
designed randomized trial, investigators may use
observational studies to examine and infer treat-
ment effects. Although retrospective observational
studies may have various types of bias, propensity
scores may reduce the impact of any imbalance in
pre-treatment patient characteristics and may
address concerns about confounding. Studies have
found fairly good agreement between treatment ef-
fects in propensity score–based observational car-
diovascular studies compared with those in
randomized trials (3).
In conclusion, despite its inherent limitations,
our study shows provocative results regarding the
potential survival beneﬁt associated with use of
inferior vena cava ﬁlters in patients with acute
venous thromboembolism and absolute or relative
contraindications to anticoagulant therapy. Weencourage further assessment of the validity of
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Effective Dose for
Cardiovascular CTWe read with interest the excellent report by Einstein
et al. (1) and the accompanying pragmatic editorial
(2). We support the laudable aim of involving
patients in the discussion of radiation exposure as
part of the clinical decision process, but we wish
to highlight a couple of areas for cardiovascular
computed tomography (CT) speciﬁcally that require
expert consensus to ensure this process is robust.
Dose calculation in cardiovascular CT is a complex
ﬁeld of medical physics, and the lack of clarity on
even the fundamentals clearly needs to be addressed.
First, the determination of an effective dose for pro-
cedures such as cardiovascular CT remains contro-
versial, while the lack of cardiovascular CT dose
reference levels and current benchmarking of insti-
tutional practice against these makes generalization
of dose potentially meaningless.
Several different conversion factors are currently
used in published reports when converting dose-
length product into an effective radiation dose (in
mSv) delivered to a patient. Aside from the fact that
these conversion factors were not designed to be
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The typical anatomical coverage of a chest and a cardiovascular
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lines, respectively. E/DLP ¼ effective dose conversion factor;
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957applied to individual patients, the variety of quoted
ﬁgures requires resolution. Those that are routinely
cited in published reports include the thoracic con-
version factors of 0.017 or 0.014 mSv/mGycm (3),
which estimate the effective dose as deﬁned in
International Commission on Radiological Protection
publication 60, and speciﬁc cardiovascular CT
conversion factors of approximately 0.028 (4),
which estimate the effective dose as deﬁned in
International Commission on Radiological Protection
publication 103. Pediatric conversion factors are even
more contentious. Because cardiovascular CT does
not usually involve scanning the whole of the thorax,
and it also predominantly involves exposure over
highly radiosensitive breast tissue, an effective dose
for any given dose-length product is proportionally
higher for cardiac versus thoracic CT (Figure 1).
The issue of dose reference levels for cardiovas-
cular CT is also important, and a recent survey of
cardiovascular CT centers in the United Kingdom
performed by the British Society of Cardiovascular CT
revealed a 5-fold variability in median dose-length
product for standard CT coronary angiography from
200 mGycm to more than 1,000 mGycm. Assuming all
images were diagnostic and scans were performed on
appropriate cardiac enabled scanners, this is alarm-
ing. However, given the evidence that the majority of
UK centers perform low volumes of scans, with only a
handful performing more than 1,000 scans each year
(5), this may not be surprising. The challenge,
however, is how to determine a suitable dose
reference level with such variation in both number
and dose.Only when we, as a clinical and scientiﬁc commu-
nity, have rationalized and agreed on these values
will discussions with our patients regarding dose be
evidence based and meaningful.Isabel Castellano, PhD
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Int J Cardiol 2013;168:3001–3.REPLY: The Murky World of Effective Dose
for Cardiovascular CTWe thank Drs. Castellano and Nicol for their interest
in our paper (1) and their many insightful comments,
which focus speciﬁcally on the radiation dose for
patients undergoing cardiovascular computed
tomography (CT). The central themes of their letter
are the challenges involved in estimating the
effective dose from the dose-length product (DLP),
the present lack of and need for diagnostic reference
levels (DRLs) for cardiovascular CT, and the great
variability in radiation doses from coronary CT
angiography (CTA). We share all of these concerns.
The thoracic conversion factors of 0.017 and
0.014 mSv $mGy1 $ cm1, which are routinely used in
published reports, are indeed inadequate for
estimating an effective dose from CTA, resulting in
substantial underestimation. As we have previously
pointed out (2), these values were derived fromMonte
Carlo simulations of ancient single-slice scanners
incapable of performing CTA and using an older
deﬁnition of effective dose. Figure 1 in the letter by
Drs. Castellano and Nicol is a wonderful illustration
of why the effective dose from coronary CTA should
be higher than that from a chest CT with the same
